Kuros Biosciences AG/ CH0325814116 /
| 15/11/2024 17:18:12 | Chg. -6.45 | Volume | Bid17:20:00 | Ask17:20:00 | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 25.00CHF | -20.51% | 28,769 Turnover: 788,496.70 |
-Bid Size: - | -Ask Size: - | 912.21 mill.CHF | - | - |
Assets
| 2017 IFRS in mill. CHF |
2018 IFRS in mill. CHF |
2019 IFRS in mill. CHF |
2020 IFRS in mill. CHF |
2021 IFRS in mill. CHF |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Property and Equipment | .6000 | .6000 | .5000 | .5000 | .6000 | ||||||
| Intangible Assets | 33.2000 | 31.1000 | 27.9000 | 23.7000 | 22.6000 | ||||||
| Long-Term Investments | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | ||||||
| Fixed Assets | 68.4000 | 66 | 64.6000 | 60.4000 | 58.4000 | ||||||
| Inventories | .2000 | .4000 | .5000 | .5000 | .5000 | ||||||
| Accounts Receivable | - | - | - | - | - | ||||||
| Cash and Cash Equivalents | 16.7000 | 18.3000 | 20.8000 | 28.4000 | 28.6000 | ||||||
| Current Assets | 17.7000 | 19.8000 | 23.3000 | 34 | 32.9000 | ||||||
| Total Assets | 86.1000 | 85.8000 | 87.9000 | 94.4000 | 91.3000 | ||||||
Liabilities
| 2017 IFRS in mill. CHF |
2018 IFRS in mill. CHF |
2019 IFRS in mill. CHF |
2020 IFRS in mill. CHF |
2021 IFRS in mill. CHF |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Accounts Payable | 1.3000 | 1.6000 | 1.1000 | .9000 | .9000 | ||||||
| Long-term debt | - | - | - | - | - | ||||||
| Liabilities to Banks | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 6.5000 | ||||||
| Provisions | 1.7000 | 2.1000 | 2.3000 | 2.7000 | 3.4000 | ||||||
| Liabilities | 12.9000 | 9.3000 | 10 | 9.8000 | 14.4000 | ||||||
| Share Capital | 8.2000 | 15.1000 | 22.5000 | 32.8000 | 3.3000 | ||||||
| Total Equity | 73.1000 | 76.5000 | 77.9000 | 84.6000 | 77 | ||||||
| Minority Interests | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | ||||||
| Total liabilities equity | 86.1000 | 85.8000 | 87.9000 | 94.4000 | 91.3000 | ||||||
Income Statement
| 2017 IFRS in mill. CHF |
2018 IFRS in mill. CHF |
2019 IFRS in mill. CHF |
2020 IFRS in mill. CHF |
2021 IFRS in mill. CHF |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | .5000 | .7000 | 2.6000 | 4 | 13.8000 | ||||||
| Depreciation (total) | - | - | - | - | - | ||||||
| Operating Result | -16.2000 | -13.7000 | -11.4000 | -13.4000 | -18.8000 | ||||||
| Interest Income | - | - | - | - | - | ||||||
| Income Before Taxes | -16.6000 | -13.8000 | -11.8000 | -12.1000 | -9.6000 | ||||||
| Income Taxes | .1000 | 2.1000 | .5000 | .6000 | 2.1000 | ||||||
| Minority Interests Profit | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | ||||||
| Net Income | -16.5000 | -11.7000 | -11.3000 | -11.5000 | -7.5000 | ||||||
Per Share
Cash Flow
| 2017 IFRS in mill. CHF |
2018 IFRS in mill. CHF |
2019 IFRS in mill. CHF |
2020 IFRS in mill. CHF |
2021 IFRS in mill. CHF |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow from Operating Activities | -10.7000 | -12.8000 | -10.8000 | -9.2000 | -5.5000 | ||||||
| Cash Flow from Investing Activities | -.9000 | -.7000 | -.1000 | -.2000 | -.4000 | ||||||
| Cash Flow from Financing | 16 | 15 | 13.1000 | 17.1000 | 6.1000 | ||||||
| Decrease / Increase in Cash | 4.4000 | 1.5000 | 2.2000 | 7.6000 | .3000 | ||||||
| Employees | 28 | 9 | 6 | 5 | 6 | ||||||
